AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

被引：0
|
作者：
Kumar, R. [1 ,2 ]
Kim, S. H. [3 ]
Zhong, D. [4 ]
Lu, S. [5 ]
Cheng, Y. [6 ]
Chen, M. [7 ]
Cho, E. [8 ]
Clay, T. [9 ]
Kang, J. -H. [10 ]
Lee, G. -W. [11 ]
Sun, M. [12 ]
Shim, B. -Y. [13 ]
Spigel, D. R. [14 ]
Yang, T. -Y. [15 ]
Wang, Q. [16 ]
Chang, G. -C. [17 ]
Yu, G. [18 ]
Wang, R. [19 ]
Luo, X. [19 ]
Zheng, H. [20 ]
Gao, R. [19 ]
Kim, H. R. [21 ]
机构：
[1] New Zealand Clin Res, Christchurch, New Zealand
[2] Univ Otago, Dept Pathol, Dunedin, New Zealand
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med,Div Hematol & Med Oncol, Seongnam, South Korea
[4] Tianjin Med Univ, Dept Oncol, Gen Hosp, Tianjin, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[6] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[7] Zhejiang Univ Canc Hosp, Dept Bioinformat, Coll Life Sci, State Key Lab Plant Physiol & Biochem, Hangzhou, Peoples R China
[8] Gachon Univ, Coll Med, Gil Med Ctr, Incheon, South Korea
[9] St John God Subaico Hosp, Dept Med Oncol, Subiaco, WA, Australia
[10] Catholic Univ Korea, Seoul St Marys Hosp, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
[11] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Div Hematol & Oncol,Dept Internal Med, Jinju, South Korea
[12] Shandong First Med Univ, Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[13] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Dept Internal Med, Suwon, South Korea
[14] Sarah Cannon Res Inst SCRI, Tennessee Oncol, PLLC, Nashville, TN USA
[15] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[16] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[17] Chung Shan Med Univ Hosp, Div Pulm Med, Dept Internal Med, Taichung, Taiwan
[18] Weifang Med Univ, Weifang Peoples Hosp, Oncol Dept, Weifang, Peoples R China
[19] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[20] BeiGene USA Inc, San Mateo, CA USA
[21] Yonsei Univ, Dept Internal Med, Yonsei Canc Ctr, Coll Med,Div Med Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
TIGIT antibody; PD-1; inhibitor; metastatic NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-07
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [31] Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
    De Boer, Richard H.
    Kotasek, Dusan
    White, Shane
    Koczwara, Bogda
    Mainwaring, Paul
    Chan, Arlene
    Melara, Rebeca
    Ye, Yining
    Adewoye, Adeboye H.
    Sikorski, Robert
    Kaufman, Peter A.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 135 (01) : 241 - 252
  • [32] Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
    Richard H. De Boer
    Dusan Kotasek
    Shane White
    Bogda Koczwara
    Paul Mainwaring
    Arlene Chan
    Rebeca Melara
    Yining Ye
    Adeboye H. Adewoye
    Robert Sikorski
    Peter A. Kaufman
    Breast Cancer Research and Treatment, 2012, 135 : 241 - 252
  • [33] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).
    Xu, Rui-Hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Phase 1/2, Dose-expansion Study of AMG 193, an MTAcooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC
    Sacher, A.
    Addeo, A.
    Doi, T.
    Chu, Q.
    El Helali, A.
    Villaruz, L.
    Prenen, H.
    Vokes, N.
    Rodon, J.
    Durm, G.
    Lebellec, L.
    O'Neil, B.
    Dy, G.
    Eggert, T.
    Keyvanjah, K.
    Gadgeel, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S350 - S351
  • [35] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka
    George, Saby
    Olencki, Thomas E.
    Tarazi, Jamal C.
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2018, 19 (03): : 405 - 415
  • [36] Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in Untreated EGFR Mutation-Positive Stage IV NSCLC: Phase 1b Outcomes
    Nakagawa, K.
    Garon, E.
    Paz-Ares, L.
    Ponce, S.
    Corral Jaime, J.
    Juan Vidal, O.
    Nadal, E.
    Kiura, K.
    Park, K.
    Widau, R.
    Alexandris, E.
    He, S.
    Lee, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2229
  • [37] Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
    Schuler, Martin
    Cho, Byoung Chuf
    Sayehli, Cyrus Michael
    Navarro, Alejandro
    Soo, Ross A.
    Richly, Heike
    Cassier, Philippe Alexandre
    Tai, David
    Penel, Nicolas
    Nagoya, Lucia
    Park, Se Hoon
    Schostak, Martin
    Gajate, Pablo
    Cathomas, Richard
    Rajagopalan, Prabhu
    Grevel, Joachim
    Bender, Sebastian
    Boix, Oliver
    Nogai, Hendrik
    Ocker, Matthias
    Eflinghaus, Peter
    Joerger, Markus
    LANCET ONCOLOGY, 2019, 20 (10): : 1454 - 1466
  • [38] Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
    Gulley, James L.
    Rajan, Arun
    Spigel, David R.
    Iannotti, Nicholas
    Chandler, Jason
    Wong, Deborah J. L.
    Leach, Joseph
    Edenfield, W. Jeff
    Wang, Ding
    Grote, Hans Juergen
    von Heydebreck, Anja
    Chin, Kevin
    Cuillerot, Jean-Marie
    Kelly, Karen
    LANCET ONCOLOGY, 2017, 18 (05): : 599 - 610
  • [39] Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
    Zhou, L.
    Yang, K. W.
    Zhang, S.
    Yan, X. Q.
    Li, S. M.
    Xu, H. Y.
    Li, J.
    Liu, Y. Q.
    Tang, B. X.
    Chi, Z. H.
    Si, L.
    Cui, C. L.
    Guo, H. Q.
    He, Z. S.
    Guo, J.
    Sheng, X.
    ANNALS OF ONCOLOGY, 2025, 36 (03) : 331 - 339
  • [40] ElevatION: NSCLC-101-A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
    Vansteenkiste, J.
    Felip, E.
    Shepherd, F.
    Paz-Ares, L.
    Barlesi, F.
    Burgers, S.
    Cai, C.
    Kiertsman, F.
    Scott, J.
    Mcculloch, T.
    Lau, Y. Y.
    Morgensztern, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2402 - S2402
12345